Quanterix Corp (QTRX) company profile
Close on Nov 17, 2026Market cap $135.26MP/E –Yield –
About Quanterix
Laboratory Analytical Instruments, SIC 3826
Quanterix Corporation is a life sciences company that provides ultra-sensitive translational research and spatial biology instruments, consumables, and laboratory services. Its proprietary Simoa platforms enable detection of protein biomarkers at concentrations down to the femtomolar range, while its spatial biology platforms allow multi-plexed cellular-level biomarker analysis in intact tissue. In addition to instruments such as the HD-X, SR-X, SP-X, PhenoCycler, and PhenoImager, the company sells consumable assay kits, reagents, and extended service contracts. It also delivers contract research services and clinical diagnostic testing, including laboratory developed tests, through its Accelerator Laboratory. Customers include research laboratories, contract research organizations, academic institutions, and bio-pharmaceutical companies.
The company distributes its products and services worldwide, supporting diagnostic and translational research primarily across neurology, oncology, and immunology. Its commercial footprint includes an installed base of more than 2,500 instruments across global research and clinical settings. Its certified Accelerator Laboratory is located in Bedford, Massachusetts.
Summary of the business section of Quanterix's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Quanterix Corp
- Founded
- 2007
- Headquarters
- Billerica, MA
- Address
- 900 Middlesex Turnpike 01821
- Phone
- (617) 301-9400
- Website
- www.quanterix.com
- Employees
- 450, Dec 31, 2025
- Industry
- Laboratory Analytical Instruments
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- QTRX
- Exchange
- Nasdaq
- IPO date
- Dec 7, 2017
- Shares outstanding
- 47M, Aug 3, 2026
- Public float
- $239.00M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1503274
- CUSIP
- 74766Q101
- ISIN
- US74766Q1013
- FIGI
- BBG0027NWC69
- Share class FIGI
- BBG0027NWC78
- EIN
- 20-8957988
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Everett Cunningham | President and CEO, Director | – |
| Masoud Toloue | President & CEO, Director | 507,310 |
| Michael Francis Miller | Chief Technology Officer | 40,634 |
| James Edward Gute Jr. | Chief Commercial Officer | – |
| Jason F. Faessler | Chief Financial Officer | – |
| Vandana Sriram | Chief Financial Officer | 31,598 |
| Benjamin Meadows | Chief Commercial Officer | 3,500 |
| Daniel Char | Chief Legal Officer | – |
| William P. Donnelly | Director | 268,765 |
| Scott Mendel | Director | 28,454 |
| Ivana Magovcevic-Liebisch | Director | 15,883 |
| Jeffrey Thomas Elliott | Director | 15,345 |
| Goldman Myla Lai | Director | 15,041 |
| Paul M. Meister | Director | 313,253 |
| Alan Bruce Sachs | Director | 70,099 |
| Karen Flynn | Director | 57,212 |
| David R. Walt | Director | 1,872,890 |
| Malcolm Garret Hampton | Director | 70,099 |
| Sarah E. Hlavinka | Director | 60,070 |
| Martin D. Madaus | Director | 291,541 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $5.25M | $1.31M | $1.40M | $14 | $125 |
| FY2024 | $6.43M | $1.35M | $2.62M | $23 | $93 |
| FY2023 | $5.44M | $10.86M | $1.61M | $59 | $94 |
| FY2022 EKevin Hrusovsky | $1.92M | -$3.81M | $1.21M | $30 | $90 |
| FY2022 Masoud Toloue | $2.96M | $1.70M | $1.21M | $30 | $90 |
| FY2021 | $4.21M | $7.59M | $1.50M | $91 | $100 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Masoud Toloue Former President and Chief Executive Officer | $670.95K | $1.17M | $2.73M | $674.17K | $5.63K | $5.25M | -18% |
| Vandana Sriram Chief Financial Officer and Treasurer | $462.25K | $427.50K | $997.50K | $309.23K | $15.75K | $2.21M | -15% |
| William P. Donnelly Former Executive Chair | $19.32K | $80.00K | $408.11K | – | $89.41K | $596.84K | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Dec 7, 2017
- Offer price
- $15.00
- Securities offered
- 4,275,200
- Gross proceeds
- $64.13M
- Exchange
- Nasdaq
- First trading day
- Dec 7, 2017
- First-day close
- $17.47+16.5%
- Lock-up ends (est.)
- Jun 5, 2018
“ Per share Total Initial public offering price $ 15.00 $ 64,128,000 Underwriting discounts and commissions (1) $ 1.05 $ 4,488,960 Proceeds to Quanterix Corporation, before expenses $ 13.95 $ 59,639,040 (1) The underwriters will receive compensation in addition to the underwriting discount.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 450 full-time employees, of which 151 worked in sales, sales support, field service, and marketing, 24 worked in engineering and research and development, 198 worked in manufacturing and operations and 77 worked in general and administration.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 8, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 14, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Feb 14, 2025 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Jan 8, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 22, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 13, 2024 | Late filing | Notification of late filing |
| Aug 18, 2020 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 2, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 2, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 7, 2017 | IPO | Initial public offering priced (424B4 prospectus) |
| Dec 6, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?